Plain-English translation of NCT05950802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing different chemotherapy preparation schedules before Yescarta (a type of immune cell therapy) in patients with a type of lymphoma that has returned or stopped responding to previous treatments. The study will try four different chemotherapy approaches—some with and without radiation—to figure out which one works best and is safest. The goal is to optimize how patients are prepared before receiving their immune cell infusion.
CAR T cell therapy is a powerful treatment, but how well it works depends partly on how the body is prepared beforehand. This trial is trying to find the best chemotherapy preparation dose and schedule to give patients the best chance of success while keeping side effects manageable.
You likely qualify if…
You likely don't qualify if…
You would first undergo leukapheresis, a procedure to collect your white blood cells, which are then sent away to be engineered into CAR T cells. While your cells are being prepared, you will receive one of four different chemotherapy regimens over several days—the study is comparing standard-dose chemotherapy, intermediate-dose chemotherapy, and versions with or without radiation therapy. After completing your chemotherapy preparation, you will receive your engineered CAR T cell infusion. The trial involves close monitoring with blood tests and imaging scans, especially in the first month, to watch for side effects and measure how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Canada